Promising Therapies to Enhance Current Treatments
Who are we?
GlobalCures' mission is to help patients be aware of potential treatment options currently available by providing them with the information and resources that will empower them with the knowledge to discuss these treatment options with their health care providers for consideration.
We achieve this mission through comprehensive research of treatment options for patients, encouraging the sharing of clinical outcomes information, and raising funds for the continued research of promising therapies.
Many potential promising therapies discovered in lab and limited studies in clinical setup never advance to clinical trials due to insufficient funding. These “financial orphans” even though they lack definitive clinical validation, they possess certain attractive attributes: their toxicity in humans is well-established, they are immediately available, and they are typically affordable. Given the many unmet medical needs, the high cost of newly approved drugs, and the long timeframe required for new drug development, it is ironic that financial orphans are largely being ignored. Consequently, numerous potentially life-saving treatments remain untapped and unavailable to patients. Globalcures addresses this issue by sharing information about these potentially promising therapies with patients so they can make a better decision by discussing it with their healthcare providers. GlobalCures also partners with Morningside center for innovative and affordable medicine, Emory University that promotes repurposed drug research, funding repurposed drug clinical studies and advocacy for effective and affordable medical treatments
Personalized, promising treatment options for your cancer type.
Has an alternative therapy worked for you? Share your successes and failures so we can help others
Clinical trials of immediately available promising treatments
Blog on Repurposed Drugs
Founder and CEO of GlobalCures, Inc.
A Note from
In June 2004, my friend Jennifer was diagnosed with a recurrence of breast cancer. As she failed one chemotherapy agent after another, I frantically searched the web for "alternative" treatments - treatments that were not in her doctor's medical bag. While I found quite a few ideas online, trying to find the few potentially promising ones became an overwhelming task. I would bring some of these treatments to my husband Vikas, a physician and cancer researcher at Harvard Medical School at Beth Israel Deaconess Medical Center in Boston, MA. While helping me to evaluate the scientific basis for these ideas, he began to sound like a broken record: "This looks interesting, but we need rigorous clinical studies to carefully evaluate toxicities and efficacy." Vikas and I continued our research and found that many of these potential therapies were not being developed. While the reasons varied somewhat, a disturbing pattern began to emerge: most of these therapies could not be patented. Thus they were not being developed by pharmaceutical companies for purely economic reasons. We knew that drug development is a time consuming and expensive process, requiring many years and millions of dollars. Pharmaceutical companies have a fiscal responsibility to their shareholders and simply cannot spend time and money developing therapies unlikely to provide a positive impact to their bottom line. Thus we discovered a "gap." Promising therapies would languish in the realm of the "unproven" unless a different drug development model was used (see Business Model). A non-profit drug development organization funded by the public, without a profit incentive, seemed to be the only way to go and so GlobalCures was born. Time ran out for Jennifer. She died at the age of 36, just nine months after her cancer recurred. But for those struggling in similar circumstances today and in the future, we hope to lead a global effort to identify, evaluate, prioritize, and develop promising medical therapies that would otherwise not be explored because of financial considerations. Our findings will be made available to patients and healthcare givers worldwide. Cancer will be our initial focus. With your help, we can make a difference to patients everywhere. Vidula Sukhatme Founder and CEO of GlobalCures, Inc.